Cabaletta Story

<div class='circular--portrait' style='background:#006400;color: #FFE4E1;font-size:4em;'>CB</div>
CABA -- USA Stock  

USD 13.04  0.58  4.26%

Cabaletta Bio is scheduled to announce its earnings today. The next fiscal quarter end is expected on the 31st of December 2020. While some baby boomers are getting worried about their positions in healthcare space, it is entirely reasonable to go over Cabaletta Bio as a possible position for your existing portfolio. We will analyze why Cabaletta Bio investors may still consider a stake in the business given the current economic outlook.
Published over a month ago
View all stories for Cabaletta Bio | View All Stories
Should you continue to hold Cabaletta Bio (NASDAQ:CABA) based on the current analyst consensus?
On a scale of 0 to 100, Cabaletta Bio holds a performance score of 8. The firm shows a Beta (market volatility) of -0.5219, which signifies possible diversification benefits within a given portfolio. Let's try to break down what Cabaletta's beta means in this case. As returns on the market increase, returns on owning Cabaletta Bio are expected to decrease at a much lower rate. During the bear market, Cabaletta Bio is likely to outperform the market. Although it is vital to follow Cabaletta Bio historical returns, it is good to be conservative about what you can do with the information regarding equity current trending patterns. The philosophy in foreseeing future performance of any stock is to evaluate the business as a whole together with its past performance, including all available fundamental and technical indicators. We have found twenty-eight technical indicators for Cabaletta Bio, which you can use to evaluate the performance of the firm. Please makes use of Cabaletta Bio information ratio, treynor ratio, and the relationship between the downside deviation and total risk alpha to make a quick decision on whether Cabaletta Bio price patterns will revert.
What is the right price you would pay to acquire a share of Cabaletta Bio? For most investors, it would be the price that gives them a wide margin of safety to have minimal downside risk. In other words, most investors are always looking for undervalued stocks. Even if the future performance is not entirely as expected, the loss of holding it is minimized, and the downside risk is negated. Please read more on our stock advisor page.

What is happening with Cabaletta Bio this year

Annual and quarterly reports issued by Cabaletta Bio are formal financial statements that are published yearly and quarterly and sent to Cabaletta stockholders. The reports show and break down the current year's ongoing operations and discuss plans for the upcoming year. Annual reports have been a requirement from the Securities and Exchange Commission (SEC) for businesses owned by the public since 1934. Companies such as Cabaletta Bio often view their annual report as an effective marketing tool to disseminate their perspective on company future earnings or innovations. With this in mind, many companies devote large sums of money to making their reports attractive and informative. In such instances, the annual report becomes a forum through which a company can communicate to the general public any number of topics that may or may not be directly related to the actual data published in the reports.

How Cabaletta utilizes its cash?

To perform a cash flow analysis of Cabaletta Bio, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Cabaletta Bio is receiving and how much cash it distributes out in a given period. The Cabaletta Bio cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities. Cabaletta Bio Net Cash Flow from Operations is projected to decrease significantly based on the last few years of reporting. The past year's Net Cash Flow from Operations was at (14.44 Million)

Sale by 5am Ventures V Lp of 10530 shares of Cabaletta Bio

Legal trades by Cabaletta Bio insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
Cabaletta insider trading alert for sale of common stock by 5am Ventures V Lp, the corporate stakeholder, on 12th of January 2021. This event was filed by Cabaletta Bio Inc with SEC on 2021-01-12. Statement of changes in beneficial ownership - SEC Form 4 [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

Is Cabaletta a risky opportunity?

Let's check the volatility. Cabaletta is looking slightly risky at this time. Whether you invest your money or manage your clients' funds, remember that it is easy to forget that behind Cabaletta (NASDAQ:CABA) stock is an actual business venture. So, do not let stock picking become an abstract concept by ignoring the elementary risk calculations. taking in a share of a Cabaletta Bio stock makes you a part-owner of that company.

Cabaletta Bio Current Consensus

Here is the current trade recommendation based on an ongoing consensus estimate among financial analysis covering Cabaletta Bio. The Cabaletta consensus assessment is calculated by taking the average estimates from all of the analysts covering Cabaletta Bio

Strong Buy
Strong Buy150.0
Strong Sell00.0

Will Cabaletta continue to rise?

Current risk adjusted performance is at 0.18. Cabaletta Bio shows above-average downside volatility for the selected time horizon. We advise investors to inspect Cabaletta Bio further and ensure that all market timing and asset allocation strategies are consistent with the estimation of Cabaletta Bio future alpha.

The Current Takeaway on Cabaletta Bio Investment

Whereas some other firms under the biotechnology industry are still a bit expensive, Cabaletta Bio may offer a potential longer-term growth to investors. On the whole, as of the 11th of December 2020, we believe that Cabaletta Bio is currently fairly valued with above average probability of distress in the next two years. However, our primary 30 days recommendation on the company is Strong Sell.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Ellen Johnson do not own shares of Cabaletta Bio. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to